MAVERIX ANNOUNCES BREAKTHROUGH ANALYTIC PLATFORM FOR NEXT GENERATION SEQUENCING DATA

Empowers Researchers to Access, Analyze, and Visualize Public and Private Genomic Data -

San Mateo CA November 7, 2012: Maverix Biomics, Inc. announces the launch of the Maverix Analytic Platform today at the American Society of Human Genetics Annual Meeting held in San Francisco, California.
Created for life science researchers, the Maverix Analytic Platform integrates the management, exploration, and visualization of genomic data into one easy-to-use system. Data is analyzed using proven, open-source algorithms and applications, and then placed into context of data from multiple other sources, including public genome databases. Results are visualized using a variety of integrated graphical tools, including the UCSC Genome Browser, the world's most widely used genome browser.


Unlike other solutions, the Maverix Analytic Platform is designed for use directly by researchers who may not have software or bioinformatics expertise. It leverages algorithms and applications developed at leading academic and research centers, and cited in over 70,000 journal articles, rather than proprietary analytic solutions. After loading sequence data from any organism (human, animal, plant, or microbe), users are immediately up and running with reliable, scientifically recommended analytic configurations at their fingertips.


Researchers can start analyzing their data using these pre-configured tools without having to invest in IT infrastructure, download software, or obtain the services of a bioinformatics expert. Novel discoveries can be made without the typical delay associated with processing large datasets. Actionable results are provided through visualizations of RNA-seq and small RNA-seq analysis, ChIP-seq analysis, SNP variant detection, ribosome profiling, bisulfite sequencing methylation analysis, and de novo small genome assembly, among others. Advanced users can customize the analysis workflows and provide their own analytic tools according to their needs.
Successful research studies require quality data. The Maverix Analytic Platform provides automated quality checks on data uploaded by users or imported directly from leading sequencing service providers to ensure valid and reliable analysis results.


The ability to search and import relevant data sets from public databases is also provided, which allows scientists to conduct their research in the context of both public and private data, further accelerating the pace of discovery.
Custom integrated UCSC Genome Browsers can be created for organisms of interest with analysis results included as persistent data tracks for visualization and further studies. Other traditional two-dimensional data visualizations are provided, such as differential expression heatmaps, box, line, and scatter plots. Visualization results can be easily shared or published.


The Maverix Analytic Platform makes collaboration and sharing of data, analytical tools, and results simple. Researchers can share their data privately or as broadly as desired; with colleagues at the next lab bench or around the world. "Communities of Discovery" can be established with other scientists around a particular organism or common research area of interest. Optional private cloud environments provide the highest level of security for proprietary data.


Automatic notifications and alerts are also provided for scientists to stay current on their research areas with minimal effort. Users will be informed of the latest relevant journal articles, availability of data sets, and release of analytic tools based on their previous performed analyses and specific areas of interest.


The Maverix "pay-as-you-go" pricing model means that users only pay for the resources they use, when they use them.


About Maverix Biomics: Based in San Mateo CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms.


NOTE TO REPORTERS: You are cordially invited to receive a personal demonstration and briefing on the Maverix Analytic Platform. The demonstration and briefing can take place at our Booth #111 at the American Society of Human Genetics conference in San Francisco on November 7, 8, or 9, or can be scheduled off site at your convenience. For more information or to schedule your demo briefing, please call Dave Mandelkern at 415-531-4238 or email [email protected]

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.